Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
KPV
An alpha-MSH tripeptide fragment studied in anti-inflammatory research.
- Half-life (approx.)
- Short tripeptide (approx., minutes)
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 5, 10 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
KPV is the C-terminal tripeptide of alpha-MSH with anti-inflammatory activity studied in colitis and skin-inflammation models. It modulates NF-κB signaling without the pigmentation effects of full melanocortin peptides. Alpha-MSH tripeptide fragment with NF-κB inhibitory activity in colitis and skin inflammation models.
Structure & identity
Tripeptide Lys-Pro-Val (α-MSH fragment)
- Sequence / structure
- Tripeptide Lys-Pro-Val (α-MSH fragment)
Mechanism
Alpha-MSH tripeptide fragment inhibits NF-κB and inflammatory cytokine release. Anti-inflammatory mechanism is receptor-context dependent — MC1R involvement varies by tissue.
Studies & clinical programs
DSS colitis mice
Published research models
- Peer-reviewed literature documents endpoints under DSS colitis mice experimental designs.
TNBS colitis
Published research models
- Peer-reviewed literature documents endpoints under TNBS colitis experimental designs.
Skin inflammation models
Published research models
- Peer-reviewed literature documents endpoints under Skin inflammation models experimental designs.
Research models in literature
- DSS colitis mice
- TNBS colitis
- Skin inflammation models
Literature highlights
- α-MSH tripeptide fragment inhibits NF-κB in DSS and TNBS colitis rodent models.
- Skin inflammation and MC1R-context assays supplement GI anti-inflammatory research.
- Short tripeptide with rapid protease turnover in systemic circulation.
Combination research notes
Fourth component of KLOW blend.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 5 | 2 | 2500.0 | 4 | 10 | 20 |
| 10 | 2 | 5000.0 | 2 | 5 | 10 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Typically reconstituted with 1–2 mL bacteriostatic water.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance